Unlocking the Science of Cannabis
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
Here is a small sampling of Benzodiazepine Use Disorder studies by title:
Ready to become a subscriber? Go to our PRICING page.
Benzodiazepines are a class of psychoactive pharmaceuticals commonly prescribed to treat anxiety, insomnia, alcohol withdrawal symptoms (e.g., delirium tremors), or panic attacks.
“Benzos,” as they are sometimes called in everyday vocabulary, have sedative, sleep-inducing (hypnotic), relaxant, and mood-improving properties that can express themselves therapeutically (see sample indications).
Conversely, excessive dosing beyond prescription may have serious adverse effects such as confusion, memory loss, dizziness, low blood pressure, reduced respiratory rates, addiction, increase in risky or pathological behavior, overdose, and death.
Speed of effect onset, the time it takes to break it down (metabolize), and potency of benzodiazepine type are direct relationship to the risk of developing benzodiazepine use disorder.
Reviews of available trials, epidemiological studies, clinical expert opinions, interviews with people suffering from benzodiazepine use disorder, and alike suggest that diazepam, lorazepam, and alprazolam tend to present a relatively higher risk of abuse potential, while oxazepam, for instance, presented with a lower one.
For practitioners, it is essential to note that benzodiazepines should always safely be tapered on a case-by-case basis to prevent severe or life-threatening withdrawal. In addition, a physician should closely supervise cannabis or cannabinoids used to reduce benzodiazepine use.
If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting CANN-DIR, published by Penn State College of Medicine.
If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting CANN-DIR, published by Penn State College of Medicine.
In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.
If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting CANN-DIR, published by Penn State College of Medicine.
Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).
However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.